Product Description
a novel positron emission tomography (PET) tracer. We conclude that [18 F]THK-5351 PET can potentially be used to detect the regional brain distribution of tau lesions in PSP, thereby facilitating the differential diagnosis of neurodegenerative disorders associated with tau protein. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27797445/)
Mechanisms of Action: Tau Imaging Agent
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institut de Recerca HSCSP
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Phase 2: Alzheimer Disease|Dementia, Vascular|Vascular System Injuries|Cognitive Dysfunction|Parkinsonian Disorders|Stroke|Tauopathies|Inflammation|Depressive Disorder, Major|Dementia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 201601675A0 | P2 |
Recruiting |
Dementia, Vascular|Stroke|Cognitive Dysfunction |
2023-11-30 |
|
| 201802299A0 | P2 |
Recruiting |
Cognitive Dysfunction|Stroke|Inflammation |
2023-07-31 |
|
| AV45+THK | P2 |
Completed |
Depressive Disorder, Major |
2021-12-28 |
|
| COFITAGE | P3 |
Active, not recruiting |
Alzheimer Disease |
2020-10-29 |